 Herpesvirus 4, Human
"Herpesvirus 4, Human" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.
| Descriptor ID |
D004854
|
| MeSH Number(s) |
B04.280.382.400.500.450 B04.909.204.210.400.500.400 B04.909.204.382.400.500.400 B04.909.574.204.500.500.400
|
| Concept/Terms |
Herpesvirus 4, Human- Herpesvirus 4, Human
- Burkitt Lymphoma Virus
- Lymphoma Virus, Burkitt
- Burkitt's Lymphoma Virus
- Burkitts Lymphoma Virus
- E-B Virus
- E B Virus
- E-B Viruses
- Infectious Mononucleosis Virus
- Infectious Mononucleosis Viruses
- Mononucleosis Virus, Infectious
- Mononucleosis Viruses, Infectious
- Epstein-Barr Virus
- Epstein Barr Virus
- Herpesvirus 4 (gamma), Human
- HHV-4
- Human Herpesvirus 4
- Burkitt Herpesvirus
- Herpesvirus, Burkitt
- EBV
|
Below are MeSH descriptors whose meaning is more general than "Herpesvirus 4, Human".
Below are MeSH descriptors whose meaning is more specific than "Herpesvirus 4, Human".
This graph shows the total number of publications written about "Herpesvirus 4, Human" by people in UAMS Profiles by year, and whether "Herpesvirus 4, Human" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 2 | 2 | | 2023 | 1 | 0 | 1 | | 2022 | 0 | 1 | 1 | | 2021 | 1 | 0 | 1 | | 2020 | 1 | 1 | 2 | | 2019 | 1 | 4 | 5 | | 2018 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2016 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2008 | 3 | 0 | 3 | | 2007 | 1 | 0 | 1 | | 2005 | 2 | 0 | 2 | | 2003 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Herpesvirus 4, Human" by people in Profiles over the past ten years.
-
Jimenez A, Carrillo LF, Carlsen ED. Systemic EBV-positive T-cell lymphoma of childhood with unusual cytogenetic findings and family history of Still's disease-associated recurrent macrophage activation syndrome. Pediatr Blood Cancer. 2024 Nov; 71(11):e31291.
-
Ashoor IF, Al-Akash S, Kizilbash S, Moudgil A, Puliyanda D, Ranabothu S, Shi Y, Dharnidharka V. Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium. Pediatr Transplant. 2024 May; 28(3):e14743.
-
Hogan CH, Owens SM, Reynoso GV, Liao Y, Meyer TJ, Zelazowska MA, Liu B, Li X, Grosskopf AK, Khairallah C, Kirillov V, Reich NC, Sheridan BS, McBride KM, Gewurz BE, Hickman HD, Forrest JC, Krug LT. Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through in vivo B cell knockout models. mBio. 2024 Feb 14; 15(2):e0299823.
-
Wang L, Howell MEA, Hensley CR, Ning K, Moorman JP, Yao ZQ, Ning S. The master antioxidant defense is activated during EBV latent infection. J Virol. 2023 11 30; 97(11):e0095323.
-
Chen J, Dai L, Kendrick S, Post SR, Qin Z. The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways. Antimicrob Agents Chemother. 2022 03 15; 66(3):e0239521.
-
Wang L, Howell MEA, Sparks-Wallace A, Zhao J, Hensley CR, Nicksic CA, Horne SR, Mohr KB, Moorman JP, Yao ZQ, Ning S. The Ubiquitin Sensor and Adaptor Protein p62 Mediates Signal Transduction of a Viral Oncogenic Pathway. mBio. 2021 10 26; 12(5):e0109721.
-
Zhao M, Nanbo A, Becnel D, Qin Z, Morris GF, Li L, Lin Z. Ubiquitin Modification of the Epstein-Barr Virus Immediate Early Transactivator Zta. J Virol. 2020 10 27; 94(22).
-
Ramos JC, Sparano JA, Chadburn A, Reid EG, Ambinder RF, Siegel ER, Moore PC, Rubinstein PG, Durand CM, Cesarman E, Aboulafia D, Baiocchi R, Ratner L, Kaplan L, Capoferri AA, Lee JY, Mitsuyasu R, Noy A. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood. 2020 09 10; 136(11):1284-1297.
-
Chen J, Kendrick S, Qin Z. Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas. Viruses. 2019 12 16; 11(12).
-
Strunz PP, Schmalzing M, Heidemeier A, Rasche L, Einsele H, Kort?m KM. Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor. Leuk Lymphoma. 2019 12; 60(14):3573-3576.
-
Nabel CS, Sameroff S, Shilling D, Alapat D, Ruth JR, Kawano M, Sato Y, Stone K, Spetalen S, Valdivieso F, Feldman MD, Chadburn A, Foss? A, van Rhee F, Lipkin WI, Fajgenbaum DC. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PLoS One. 2019; 14(6):e0218660.
-
Wang L, Howell MEA, Sparks-Wallace A, Hawkins C, Nicksic CA, Kohne C, Hall KH, Moorman JP, Yao ZQ, Ning S. p62-mediated Selective autophagy endows virus-transformed cells with insusceptibility to DNA damage under oxidative stress. PLoS Pathog. 2019 04; 15(4):e1007541.
-
Gao Y, Wang L, Lei Z, Li J, Forrest JC, Liang X. IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells. J Gen Virol. 2019 05; 100(5):851-862.
-
Manzano M, Patil A, Waldrop A, Dave SS, Behdad A, Gottwein E. Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma. Nat Commun. 2018 08 15; 9(1):3263.
-
Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
-
Montgomery ND, Coward WB, Johnson S, Yuan J, Gulley ML, Mathews SP, Kaiser-Rogers K, Rao KW, Sanger WG, Sanmann JN, Fedoriw Y. Karyotypic abnormalities associated with Epstein-Barr virus status in classical Hodgkin lymphoma. Cancer Genet. 2016 09; 209(9):408-416.
-
Haverkos BM, Gru AA, Geyer SM, Bingman AK, Hemminger JA, Mishra A, Wong HK, Pancholi P, Freud AG, Caligiuri MA, Baiocchi RA, Porcu P. Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S181-S190.e4.
-
Samdani RT, Hechtman JF, O'Reilly E, DeMatteo R, Sigel CS. EBV-associated lymphoepithelioma-like carcinoma of the pancreas: Case report with targeted sequencing analysis. Pancreatology. 2015 May-Jun; 15(3):302-4.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|